The current price of ARVN is $6.55 — it has decreased by 11.73% since the previous close. Data as of Nov 5, 2026.
ARVN is down 17.09% over the past week, down 12.20% over the past month and down 31.56% over the past year. The price is below its 200-day moving average of $9.61.
Analysts' average 12-month price target for ARVN is $14.00, which implies 113.74% upside from the current price. Individual estimates range from $10.00 to $20.00.
Of the 15 analysts covering Arvinas, Inc., 2 rate it a strong buy, 5 rate it a buy and 8 rate it a hold. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.
Arvinas, Inc. has a market capitalization of $428.28M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Arvinas, Inc. posted a loss of $0.82 per share against an estimate of -$0.9177, beating expectations by 10.65%. Upcoming reports are listed in the earnings calendar.
Arvinas, Inc. reported revenue of $500K in its most recent quarter, which has decreased by 98.81% compared with the same quarter a year earlier. Analysts had expected $12.39M.
Arvinas, Inc. has not paid any dividends over the past year.
Companies most comparable to Arvinas, Inc. include Kymera Therapeutics, Inc., Nurix Therapeutics, Inc., Monte Rosa Therapeutics, Inc., C4 Therapeutics, Inc. and Foghorn Therapeutics Inc.
In the latest trading session ARVN moved between $6.52 and $7.43, a range of 13.96% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Arvinas, Inc. shows a strong sell rating today and a strong sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Arvinas, Inc. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks ARVN has traded between $6.52 and $14.51. The current price is 54.86% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.